These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

776 related items for PubMed ID: 25903340

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.
    Schmidt MR, McGinnes-Cullen LW, Kenward SA, Willems KN, Woodland RT, Morrison TG.
    J Virol; 2014 Sep 01; 88(17):10165-76. PubMed ID: 24965456
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B, Matsuoka Y, Le Nouën C, Liu X, Herbert R, Swerczek J, Santos C, Paneru M, Collins PL, Buchholz UJ, Munir S.
    J Virol; 2020 Dec 22; 95(2):. PubMed ID: 33115876
    [Abstract] [Full Text] [Related]

  • 8. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
    Liang B, Ngwuta JO, Surman S, Kabatova B, Liu X, Lingemann M, Liu X, Yang L, Herbert R, Swerczek J, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Collins PL, Munir S.
    J Virol; 2017 Aug 01; 91(15):. PubMed ID: 28539444
    [Abstract] [Full Text] [Related]

  • 9. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
    Schneider-Ohrum K, Cayatte C, Bennett AS, Rajani GM, McTamney P, Nacel K, Hostetler L, Cheng L, Ren K, O'Day T, Prince GA, McCarthy MP.
    J Virol; 2017 Apr 15; 91(8):. PubMed ID: 28148790
    [Abstract] [Full Text] [Related]

  • 10. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.
    McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Schmidt MR, Morrison TG.
    J Virol; 2011 Jan 15; 85(1):366-77. PubMed ID: 20980510
    [Abstract] [Full Text] [Related]

  • 11. The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV.
    Cullen LM, Schmidt MR, Morrison TG.
    Hum Vaccin Immunother; 2017 Dec 02; 13(12):2814-2823. PubMed ID: 28604155
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X, Liang B, Ngwuta J, Liu X, Surman S, Lingemann M, Kwong PD, Graham BS, Collins PL, Munir S.
    J Virol; 2017 Nov 15; 91(22):. PubMed ID: 28835504
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection.
    Qiao L, Zhang Y, Chai F, Tan Y, Huo C, Pan Z.
    Antiviral Res; 2016 Jul 15; 131():131-40. PubMed ID: 27154395
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
    Zhang L, Durr E, Galli JD, Cosmi S, Cejas PJ, Luo B, Touch S, Parmet P, Fridman A, Espeseth AS, Bett AJ.
    Vaccine; 2018 Dec 18; 36(52):8119-8130. PubMed ID: 30340881
    [Abstract] [Full Text] [Related]

  • 20. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.
    Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Heaton PM, Fraire AE, Morrison TG.
    J Virol; 2010 Jan 18; 84(2):1110-23. PubMed ID: 19889768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.